Tag Archives: Xtandi

Update from India on Xtandi (Enzalutamide) for cancer treatment

In January 2016, KEI and the Union for Affordable Cancer Treatment petitioned the US the Department of Health and Human Services or the National Institutes of Health to use the federal government rights in the patents on the prostate cancer … Continue reading

Posted in Cancer, Drug prices, Patent, Uncategorized | Tagged , , , | Leave a comment

Patent denied, price of prostate cancer drug may go down

The Indian Patent Office recently denied a patent for the drug Xtandi (Enzalutamide) by Japanese firm Astellas Pharma used in  treatment of prostate cancer. This decision comes in the light of the pre-grant opposition filed by pharma companies BDR Pharma, drug … Continue reading

Posted in Bayh Dole Act, March in rights, Patent, Patent Opposition, Sec 3 (d), Uncategorized | Tagged | Leave a comment